DATA GRAPHICS | Product Development
LAG3 beyond BMS at ASCO21: Data Byte
A crop of readouts from compounds against LAG3 strengthen the case for the next-generation checkpoint target
May 24, 2021 11:35 PM UTC
BMS grabbed headlines with its Phase III data at ASCO21, but its anti-LAG3 mAb is just one of at least six compounds with clinical data at the meeting.
At least four other mAbs will have Phase I data in first- or later-line settings for various solid tumors at the American Society of Clinical Oncology (ASCO) virtual conference. And a pair of abstracts cover clinical data for LAG3 fusion protein eftilagimod from Immutep Ltd. (NASDAQ:IMMP; ASX:IMM)...